{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:40:02Z","timestamp":1783413602271,"version":"3.54.6"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.3816\/clc.2006.s.012","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T21:02:25Z","timestamp":1221166945000},"page":"S36-S42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"S1","title":["Non-Rash Skin Toxicities Associated with Novel Targeted Therapies"],"prefix":"10.3816","volume":"8","author":[{"given":"Mario E.","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Boerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLC.2006.s.012_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1126\/science.7618085","article-title":"Strain-dependent epithelial defects in mice lacking the EGF receptor","volume":"269","author":"Sibilia","year":"1995","journal-title":"Science"},{"key":"10.3816\/CLC.2006.s.012_bib2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/1523-1747.ep12874601","article-title":"Immunolocalization of epidermal growth factor receptors in normal developing human skin","volume":"94","author":"Nanney","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1126\/science.7618084","article-title":"Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype","volume":"269","author":"Threadgill","year":"1995","journal-title":"Science"},{"key":"10.3816\/CLC.2006.s.012_bib4","first-page":"26","article-title":"Pathology and management of dermatologic toxicities associated with anti-EGFR therapy","volume":"20","author":"Fox","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"10.3816\/CLC.2006.s.012_bib5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2230.2006.02223.x","article-title":"Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor","volume":"31","author":"Lacouture","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib6","unstructured":"Wang D, Boerner SA, Winkler JD, et al. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta (In press)."},{"issue":"16 suppl","key":"10.3816\/CLC.2006.s.012_bib7","first-page":"194s","article-title":"A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer","volume":"23","author":"Lorusso","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib8","first-page":"236","article-title":"The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors","volume":"4","author":"Lacouture","year":"2006","journal-title":"J Support Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","article-title":"Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours","volume":"151","author":"Jacot","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.3816\/CLC.2006.s.012_bib11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CLC.2006.s.012_bib12","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","article-title":"Complications of therapy in cancer patients: case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Chang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s004030050469","article-title":"Maintenance of human skin in organ culture: role for insulin-like growth factor-1 receptor and epidermal growth factor receptor","volume":"291","author":"Tavakkol","year":"1999","journal-title":"Arch Dermatol Res"},{"key":"10.3816\/CLC.2006.s.012_bib16","doi-asserted-by":"crossref","first-page":"6388S","DOI":"10.1158\/1078-0432.CCR-040028","article-title":"Kinase inhibition with BAY 43-9006 in renal cell carcinoma","volume":"10","author":"Ahmad","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLC.2006.s.012_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.3816\/CLC.2006.s.012_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S1548-5315(11)70630-1","article-title":"Managing cutaneous side effects of epidermal growth factor receptor (HER1\/EGFR) inhibitors","volume":"2","author":"Dick","year":"2005","journal-title":"Commun Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"Oncologist"},{"key":"10.3816\/CLC.2006.s.012_bib20","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archderm.138.1.129","article-title":"Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors","volume":"138","author":"Kimyai-Asadi","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1200\/JCO.1993.11.5.959","article-title":"Phase I evaluation of all-trans-retinoic acid in adults with solid tumors","volume":"11","author":"Lee","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.2005.04.057","article-title":"Practical management of patients with nonsmall-cell lung cancer treated with gefitinib","volume":"23","author":"Shah","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib25","first-page":"1251","article-title":"Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene","volume":"6","author":"Batra","year":"1995","journal-title":"Cell Growth Differ"},{"key":"10.3816\/CLC.2006.s.012_bib26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrm1619","article-title":"The cornified envelope: a model of cell death in the skin","volume":"6","author":"Candi","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.3816\/CLC.2006.s.012_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrg758","article-title":"Getting under the skin of epidermal morphogenesis","volume":"3","author":"Fuchs","year":"2002","journal-title":"Nat Rev Genet"},{"key":"10.3816\/CLC.2006.s.012_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/BF03187327","article-title":"Immunohistochemical localization of transforming growth factor-alpha and epithelial growth factor receptor in human fetal developing skin, psoriasis and restrictive dermopathy","volume":"6","author":"Sergi","year":"2000","journal-title":"Pathol Oncol Res"},{"key":"10.3816\/CLC.2006.s.012_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib30","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2133.2006.07452.x","article-title":"The PRIDE (Papulopustules and\/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome","volume":"155","author":"Lacouture","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition","volume":"20","author":"Albanell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/1523-1747.ep12263298","article-title":"Distribution of epidermal growth factor receptors in rat tissues during embryonic skin development, hair formation, and the adult hair growth cycle","volume":"83","author":"Green","year":"1984","journal-title":"J Invest Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/(SICI)1097-0029(19981201)43:5<444::AID-JEMT10>3.0.CO;2-C","article-title":"Contributions of the epidermal growth factor receptor to keratinocyte motility","volume":"43","author":"Hudson","year":"1998","journal-title":"Microsc Res Tech"},{"key":"10.3816\/CLC.2006.s.012_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ar.1092050107","article-title":"Epidermal growth factor delays the development of the epidermis and hair follicles of mice during growth of the first coat","volume":"205","author":"Moore","year":"1983","journal-title":"Anat Rec"},{"key":"10.3816\/CLC.2006.s.012_bib35","first-page":"1959","article-title":"Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development","volume":"150","author":"Hansen","year":"1997","journal-title":"Am J Pathol"},{"key":"10.3816\/CLC.2006.s.012_bib36","first-page":"505","article-title":"The EGF receptor -an essential regulator of multiple epidermal functions","volume":"10","author":"Jost","year":"2000","journal-title":"Eur J Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/02841860310006038","article-title":"Epidermal growth factor receptor inhibition induces trichomegaly","volume":"42","author":"Dueland","year":"2003","journal-title":"Acta Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bjo.87.1.119","article-title":"Congenital trichomegaly (Oliver-McFarlane syndrome): a case report with 9 years' follow up","volume":"87","author":"Haritoglou","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.3816\/CLC.2006.s.012_bib39","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.jaad.2004.05.002","article-title":"Hypertrichosis of the eyelashes caused by bimatoprost","volume":"51","author":"Tosti","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000065852","article-title":"Trichomegaly of the eyelashes in dermatomyositis","volume":"205","author":"Sharma","year":"2002","journal-title":"Dermatology"},{"key":"10.3816\/CLC.2006.s.012_bib41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/(SICI)1096-9098(199807)68:3<199::AID-JSO13>3.0.CO;2-X","article-title":"Acquired hypertrichosis lanuginosa: case report and review of the literature","volume":"68","author":"Farina","year":"1998","journal-title":"J Surg Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib42","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"16","author":"Bouche","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib43","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2004.06265.x","article-title":"Trichomegaly following treatment with gefitinib (ZD1839)","volume":"151","author":"Pascual","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib44","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLC.2006.s.012_bib45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/jpet.103.052530","article-title":"Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans","volume":"307","author":"Moss","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3816\/CLC.2006.s.012_bib46","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1096\/fj.00-0368com","article-title":"SCF\/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit","volume":"15","author":"Botchkareva","year":"2001","journal-title":"Faseb J"},{"key":"10.3816\/CLC.2006.s.012_bib47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2005.07010.x","article-title":"Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab","volume":"154","author":"Shu","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib48","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1200\/JCO.2003.04.169","article-title":"Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab","volume":"21","author":"Monti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.012_bib49","series-title":"Tarceva [package insert]","year":"2005"},{"key":"10.3816\/CLC.2006.s.012_bib50","series-title":"Erbitux [package insert]","year":"2006"},{"key":"10.3816\/CLC.2006.s.012_bib51","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2002.124621","article-title":"Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody","volume":"47","author":"Boucher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib52","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000073100","article-title":"Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor","volume":"207","author":"Dainichi","year":"2003","journal-title":"Dermatology"},{"key":"10.3816\/CLC.2006.s.012_bib53","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2230.1986.tb00439.x","article-title":"Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects","volume":"11","author":"Baran","year":"1986","journal-title":"Clin Exp Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib54","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-143-4-200508160-00021","article-title":"Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?","volume":"143","author":"Robert","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLC.2006.s.012_bib55","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/07357900600814847","article-title":"Three case reports of hand-foot syndrome with gefitinib","volume":"24","author":"Razis","year":"2006","journal-title":"Cancer Invest"},{"key":"10.3816\/CLC.2006.s.012_bib56","first-page":"1781","article-title":"Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment","volume":"13","author":"Comandone","year":"1993","journal-title":"Anticancer Res"},{"key":"10.3816\/CLC.2006.s.012_bib57","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1078155206069242","article-title":"Management of hand-foot syndrome induced by capecitabine","volume":"12","author":"Gressett","year":"2006","journal-title":"J Oncol Pharm Pract"},{"key":"10.3816\/CLC.2006.s.012_bib58","first-page":"1097","article-title":"Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy","volume":"6","author":"Ellerhorst","year":"1999","journal-title":"Oncol Rep"},{"key":"10.3816\/CLC.2006.s.012_bib59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/archderm.1995.01690140086015","article-title":"Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent","volume":"131","author":"Zimmerman","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLC.2006.s.012_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1014421912799","article-title":"Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome\u2013recall following different chemotherapy agents","volume":"20","author":"Hui","year":"2002","journal-title":"Invest New Drugs"},{"key":"10.3816\/CLC.2006.s.012_bib61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1188\/05.CJON.103-106","article-title":"Palmar-plantar erythrodysesthesia","volume":"9","author":"Wilkes","year":"2005","journal-title":"Clin J Oncol Nurs"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411705344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411705344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:00:21Z","timestamp":1761505221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730411705344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":61,"alternative-id":["S1525730411705344"],"URL":"https:\/\/doi.org\/10.3816\/clc.2006.s.012","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-Rash Skin Toxicities Associated with Novel Targeted Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLC.2006.s.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}